MCID: JPN002
MIFTS: 54

Japanese Encephalitis malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Japanese Encephalitis

About this section
Sources:
2CDC, 11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Japanese Encephalitis:

Name: Japanese Encephalitis 11 48 54 2 13 68
Je 48 2
Japanese B Encephalitis 11
 
Encephalitis, Japanese 39
Encephalitis Japanese 50

Characteristics:

Orphanet epidemiological data:

54
japanese encephalitis:
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology11 DOID:10844
ICD1030 A83.0
ICD9CM32 062.0
MeSH39 D004672
NCIt45 C34577
Orphanet54 ORPHA79139
MESH via Orphanet40 D004672
UMLS via Orphanet69 C0014057
ICD10 via Orphanet31 A83.0

Summaries for Japanese Encephalitis

About this section
CDC:2 Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia and the western Pacific. For most travelers to Asia, the risk for JE is very low but varies based on destination, duration of travel, season, and activities. JE virus is maintained in a cycle involving mosquitoes and vertebrate hosts, mainly pigs and wading birds. Humans can be infected when bitten by an infected mosquito. Most human infections are asymptomatic or result in only mild symptoms. However, a small percentage of infected persons develop inflammation of the brain (encephalitis), with symptoms including sudden onset of headache, high fever, disorientation, coma, tremors and convulsions. About 1 in 4 cases are fatal. There is no specific treatment for JE. Patient management focuses on supportive care and management of complications. Steps to prevent JE include using personal protective measures to prevent mosquito bites and vaccination.

MalaCards based summary: Japanese Encephalitis, also known as je, is related to aseptic meningitis and west nile virus, and has symptoms including headache, high fever and neck stiffness. An important gene associated with Japanese Encephalitis is CD209 (CD209 Molecule), and among its related pathways are Cytokines and Inflammatory Response and Dendritic Cells Developmental Lineage Pathway. Affiliated tissues include brain, brain and t cells, and related mouse phenotypes are homeostasis/metabolism and hematopoietic system.

Disease Ontology:11 A viral infectious disease that results in infection located in brain, has material basis in Japanese encephalitis virus, which is transmitted by Culex tritaeniorhynchus mosquito bite. The infection has symptom headache, has symptom high fever, has symptom neck stiffness, has symptom stupor, has symptom disorientation, has symptom coma, has symptom tremors, has symptom convulsions, and has symptom spastic paralysis.

Wikipedia:71 Japanese encephalitis (JE), formerly known as Japanese B encephalitis to distinguish it from Economo\'s... more...

Related Diseases for Japanese Encephalitis

About this section

Diseases related to Japanese Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 98)
idRelated DiseaseScoreTop Affiliating Genes
1aseptic meningitis29.6CLEC4G, DDX58
2west nile virus29.2CD209, CLEC4M, DDX58, HELLS, TLR3
3myelitis29.0CXCL10, IFNB1, TNF
4encephalitis10.9
5humeroradioulnar synostosis10.4DDX58, IFNB1
6secretory diarrhea10.3DDX58, IFNB1
7listeriosis10.2IFNB1, TLR3
8aleutian mink disease10.2DDX58, IFNB1
9streptococcal meningitis10.2IFNB1, TNF
10mastocytosis cutaneous with short stature conductive hearing loss and microtia10.1CD209, TNF
11pancreatic solid pseudopapillary carcinoma10.0HELLS, TNF
12steatorrhea10.0CXCL10, TNF
13atypical depressive disorder10.0CXCL10, TNF
14oesophagostomiasis10.0IFNB1, TNF
15non-langerhans-cell histiocytosis10.0CD209, IFNB1, TNF
16progressive relapsing multiple sclerosis9.9CXCL10, IFNB1
17neuronitis9.9
18erythema multiforme9.9CD209, CXCL10, TLR3
19murray valley encephalitis9.9
20macular amyloidosis9.9CXCL10, TNF
21hereditary ataxia9.8CLEC4M, DDX58, TNF
22dentin dysplasia9.8CD209, CXCL10, TNF
23binocular vision disease9.8CXCL10, TNF
24dentinogenesis imperfecta9.8CD209, TLR3, TNF
25whipple disease9.8DDX58, IFNB1, TNF
26neuroblastoma9.8
27malaria9.8
28tick-borne encephalitis9.8
29endotheliitis9.8
30human monocytic ehrlichiosis9.8CCL5, CD209, DDX58
31primary orthostatic tremor9.7CCL5, TNF
32toxic maculopathy9.7CXCL10, TNF
33hereditary hemorrhagic telangiectasia9.7IFNB1, TLR3, TNF
34hypokalemia9.7CXCL10, DDX58, TNF
35intracranial hemorrhage in brain cerebrovascular malformations9.7CXCL10, IFNB1, TNF
36sterility due to immotile flagella9.7CCL5, TNF
37orbital lymphangioma9.7CCL5, TNF
38viral encephalitis9.7
39yellow fever9.7
40nervous system disease9.7CD209, DDX58, IFNB1, TLR3
41medulloblastoma9.6
42dengue hemorrhagic fever9.6
43chikungunya9.6
44filariasis9.6
45hemiplegia9.6
46rabies9.6
47cerebritis9.6
48herpes simplex9.6
49meningitis9.6
50hemorrhagic fever9.6

Graphical network of the top 20 diseases related to Japanese Encephalitis:



Diseases related to japanese encephalitis

Symptoms & Phenotypes for Japanese Encephalitis

About this section

Symptoms:

 11 (show all 9)
  • headache
  • high fever
  • neck stiffness
  • stupor
  • disorientation
  • coma
  • tremors
  • convulsions
  • spastic paralysis

MGI Mouse Phenotypes related to Japanese Encephalitis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053767.4CLEC4G, CLEC4M, CXCL10, DDX58, HELLS, IFNB1
2MP:00053976.9CCL5, CLEC4G, CLEC4M, CXCL10, DDX58, HELLS
3MP:00053876.1CCL5, CLEC4G, CLEC4M, CXCL10, DDX58, HELLS

Drugs & Therapeutics for Japanese Encephalitis

About this section

Drugs for Japanese Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EthanolapprovedPhase 4204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
2AntibodiesPhase 4, Phase 3, Phase 2, Phase 16045
3VaccinesPhase 4, Phase 3, Phase 2, Phase 16428
4ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16045
5
Aluminum hydroxideapprovedPhase 3, Phase 120121645-51-2
Synonyms:
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
 
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
6Protective AgentsPhase 37190
7DEETPhase 32
8Insect RepellentsPhase 33
9
LactitolPhase 3332585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
10Heptavalent Pneumococcal Conjugate VaccinePhase 3454
11Pharmaceutical SolutionsPhase 37793
12
RibavirinapprovedPhase 298436791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
13
Neomycinapproved, vet_approvedPhase 1, Phase 2481404-04-28378
Synonyms:
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
11025-81-3
119-04-0
1393-86-8
1404-04-2
1405-10-3 (sulfate (salt))
4-18-00-07476 (Beilstein Handbook Reference)
72131_FLUKA
AB00443887
AC1L1QVH
Actilin
Actiline
Antibiotic 10676
Antibiotic produced by Streptomyces decaris. Neomycin B
Antibiotique
BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG
BDG-(1-4)NEB-(5-1)RIB-(3-1)NED
BPBio1_000326
BRN 0101621
BSPBio_000296
C01737
C23H46N6O13
C25H50N6O13
CCRIS 5462
CHEBI:7508
CID8378
Caswell No. 595
D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
D05140
DB00452
DB00994
EINECS 204-292-2
EINECS 215-766-3
EPA Pesticide Chemical Code 006303
Endomixin
Enterfram
Fradiomycin
Fradiomycin B
Fradiomycinum
Framicetina
Framicetina [INN-Spanish]
Framycetin
Framycetin (INN)
Framycetin [INN:BAN:DCF]
Framycetine
Framycetine [INN-French]
Framycetinum
Framycetinum [INN-Latin]
 
Framygen
Fraquinol
HMS2089P15
HSDB 3242
LS-96091
LS-96095
MolPort-003-938-736
Myacine
Myacyne
Mycifradin
Myciguent
N1142_SIGMA
NCGC00179612-01
NEOMYCIN AND POLYMYXIN B SULFATES
NEOMYCIN B
NEOMYCIN SULFATE
NMY
Neo-Fradin
Neo-Rx
Neobiotic
Neobrettin
Neolate
Neomas
Neomcin
Neomicina
Neomicina [DCIT]
Neomin
Neomycin B Sulfate
Neomycin B sulfate
Neomycin Sulfate
Neomycin Sulphate
Neomycin solution
Neomycine
Neomycine [INN-French]
Neomycinum
Neomycinum [INN-Latin]
Nivemycin
PIMAVECORT
Prestwick3_000158
ST075177
Soframycin
Soframycin Ophthalmic
Soframycine
Tuttomycin
UNII-4BOC774388
UNII-I16QD7X297
USAF CB-19
VONAMYCIN
Vonamycin powder V
neomycin
14AntimetabolitesPhase 211774
15Anti-Infective AgentsPhase 221402
16Antiviral AgentsPhase 29732
17Rho(D) Immune GlobulinPhase 2317
18gamma-GlobulinsPhase 2317
19Immunoglobulins, IntravenousPhase 2324
20Aluminum sulfatePhase 187

Interventional clinical trials:

(show top 50)    (show all 78)
idNameStatusNCT IDPhase
1Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in ChildrenUnknown statusNCT01954810Phase 4
2Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis VaccineUnknown statusNCT01398540Phase 4
3A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2CompletedNCT01656200Phase 4
4Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesCompletedNCT02643433Phase 4
5Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAXCompletedNCT02526550Phase 4
6This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedNCT01158599Phase 4
7Post-licensure Safety Study of IMOJEV® in ThailandCompletedNCT01981967Phase 4
86-year Antibody Check After Third Vaccination Against Japanese EncephalitisCompletedNCT02039440Phase 4
9Lot-to-lot Consistency Trial of JE Live Attenuated SA 14-14-2 VaccineCompletedNCT01567865Phase 4
10Immunogenicity of SA 14-14-2 JE VaccineCompletedNCT01635816Phase 4
11Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE VaccineCompletedNCT01815073Phase 4
12Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis VaccineinjRecruitingNCT02532569Phase 4
13Postmarketing Surveillance Study for IMOJEV® in Republic of KoreaRecruitingNCT02933710Phase 4
14Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella VaccineRecruitingNCT02880865Phase 4
15Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster DoseActive, not recruitingNCT02514746Phase 4
16Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDRUnknown statusNCT00938379Phase 3
17Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in ToddlersCompletedNCT01396512Phase 3
18A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and ToddlersCompletedNCT01092507Phase 3
19Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccineCompletedNCT00249769Phase 3
20Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51CompletedNCT00596102Phase 3
21Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in ToddlersCompletedNCT01001988Phase 3
22Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVCompletedNCT01190228Phase 3
23Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 3
24Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of AgeCompletedNCT00463684Phase 3
25Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00595790Phase 3
26Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595270Phase 3
27Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00604708Phase 3
28Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE VaccineCompletedNCT00463476Phase 3
29Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese EncephalitisCompletedNCT01386827Phase 3
30Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy SubjectsCompletedNCT02492165Phase 3
31Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedNCT00605085Phase 3
32Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccineCompletedNCT00412516Phase 3
33Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the PhilippinesCompletedNCT00735644Phase 3
34Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai ChildrenCompletedNCT01408537Phase 3
35Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult SubjectsCompletedNCT01662440Phase 3
36A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAXCompletedNCT00314145Phase 3
37Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00595465Phase 3
38A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese InfantsCompletedNCT02367664Phase 3
39Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00594958Phase 3
40Study of a Booster Dose of IMOJEV® Vaccine One Year After Primary Immunization in Healthy Children in South KoreaCompletedNCT01900444Phase 3
41Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedNCT01041573Phase 3
42Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440CompletedNCT00596271Phase 3
43Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.CompletedNCT00314132Phase 3
44Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedNCT01296360Phase 3
45Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595309Phase 3
46Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedNCT00776230Phase 3
47Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesCompletedNCT01047839Phase 3
48Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in KoreaCompletedNCT01150942Phase 3
49Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedNCT01246479Phase 3
50A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3

Search NIH Clinical Center for Japanese Encephalitis


Cochrane evidence based reviews: encephalitis, japanese

Genetic Tests for Japanese Encephalitis

About this section

Anatomical Context for Japanese Encephalitis

About this section

MalaCards organs/tissues related to Japanese Encephalitis:

36
Brain, T cells, B cells, Testes, Endothelial, Kidney, Monocytes

FMA organs/tissues related to Japanese Encephalitis:

17
Brain

Publications for Japanese Encephalitis

About this section

Articles related to Japanese Encephalitis:

(show top 50)    (show all 671)
idTitleAuthorsYear
1
How Zoophilic Japanese Encephalitis Vector Mosquitoes Feed on Humans. (28082626)
2017
2
Antisense Oligonucleotides Targeting Raf-1 Block Japanese Encephalitis Virus In Vitro and In Vivo. (28051352)
2017
3
Diagnostic dilemma-dengue or Japanese encephalitis? (28084251)
2017
4
Interactions of human microglia cells with Japanese encephalitis virus. (28088249)
2017
5
Inhibition of Japanese encephalitis virus (JEV) replication by specific RNA aptamer against JEV methyltransferase. (27986564)
2017
6
Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children. (27846060)
2017
7
Dual infection with Japanese encephalitis and dengue fever: Issues with diagnosis. (28084252)
2017
8
Mx Is Not Responsible for the Antiviral Activity of Interferon-I+ against Japanese Encephalitis Virus. (28075421)
2017
9
Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. (27903416)
2017
10
European Aedes albopictus and Culex pipiens are Competent Vectors for Japanese Encephalitis Virus. (28085881)
2017
11
GRP78 is an important host-factor for Japanese encephalitis virus entry and replication in mammalian cells. (28053106)
2017
12
Introducing a cleavable signal peptide enhances the packaging efficiency of lentiviral vectors pseudotyped with Japanese encephalitis virus envelope proteins. (27993624)
2017
13
Mechanism of Japanese encephalitis virus genotypes replacement based on human, porcine and mosquito-originated cell lines model. (27086150)
2016
14
The NS3 and NS4A genes as the targets of RNA interference inhibit replication of Japanese encephalitis virus in vitro and in vivo. (27593564)
2016
15
Reemergence of Japanese Encephalitis in South Korea, 2010-2015. (27648677)
2016
16
Can we differentiate between herpes simplex encephalitis and Japanese encephalitis? (27288787)
2016
17
Eco-friendly larvicides from Indian plants: Effectiveness of lavandulyl acetate and bicyclogermacrene on malaria, dengue and Japanese encephalitis mosquito vectors. (27504617)
2016
18
A large outbreak of Japanese encephalitis predominantly among adults in northern region of West Bengal, India. (27096294)
2016
19
In vitro and in vivo characterization of chimeric duck Tembusu flavivirus based on Japanese encephalitis live vaccine strain SA14-14-2. (27100268)
2016
20
Argonaute 2 Suppresses the Infection of Japanese Encephalitis Virus in Aedes aegypti. (27169949)
2016
21
Sublingual immunization with Japanese encephalitis virus vaccines induces effective immunity through both cellular and humoral immune responses in mice. (28004418)
2016
22
Production of Japanese Encephalitis Virus-Like Particles Using Insect Cell Expression Systems. (27076311)
2016
23
One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. (26994987)
2016
24
A tropical menace of co-infection of Japanese encephalitis and neurocysticercosis in two children. (27606026)
2016
25
Apraxia of eyelid closure in a case of post-Japanese encephalitis Parkinsonism. (27147166)
2016
26
DC-SIGN as an attachment factor mediates Japanese encephalitis virus infection of human dendritic cells via interaction with a single high-mannose residue of viral E glycoprotein. (26629951)
2016
27
Knowledge Obtained from an Elderly Case of Japanese Encephalitis. (27580555)
2016
28
A simple method for developing an infectious cDNA clone of Japanese encephalitis virus. (27665292)
2016
29
Serological evidence of widespread West Nile virus and Japanese encephalitis virus infection in native domestic ducks (Anas platyrhynchos var domesticus) in Kuttanad region, Kerala, India. (27638121)
2016
30
Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus. (27139722)
2016
31
Pharmacodynamics of aminoglycosides and tetracycline derivatives against Japanese encephalitis virus. (26972394)
2016
32
Pre-cut Filter Paper for Detecting Anti-Japanese Encephalitis Virus IgM from Dried Cerebrospinal Fluid Spots. (26986061)
2016
33
A collaborative study of an alternative in vitro potency assay for the Japanese encephalitis vaccine. (27497622)
2016
34
Intensive Circulation of Japanese Encephalitis Virus in Peri-urban Sentinel Pigs near Phnom Penh, Cambodia. (27926937)
2016
35
Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China. (27560360)
2016
36
Sphingomyelin generated by sphingomyelin synthase 1 is involved in attachment and infection with Japanese encephalitis virus. (27892528)
2016
37
Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses. (27090635)
2016
38
Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. (27628323)
2016
39
Transmembrane Domains of NS2B Contribute to Both Viral RNA Replication and Particle Formation in Japanese Encephalitis Virus. (27053551)
2016
40
The ubiquitin-proteasome system is essential for the productive entry of Japanese encephalitis virus. (27567260)
2016
41
A KDEL Retrieval System for ER-Golgi Transport of Japanese Encephalitis Viral Particles. (26861384)
2016
42
Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIAROAr in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. (27460550)
2016
43
Neutralizing activities of human immunoglobulin derived from donors in Japan against mosquito-borne flaviviruses, Japanese encephalitis virus, West Nile virus, and dengue virus. (27462140)
2016
44
Long-Term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization. (28030526)
2016
45
The Spatio-temporal Distribution of Japanese Encephalitis Cases in Different Age Groups in Mainland China, 2004 - 2014. (27050414)
2016
46
Japanese Encephalitis. (27450609)
2016
47
Caveolin-1-mediated Japanese encephalitis virus entry requires a two-step regulation of actin reorganization. (26986451)
2016
48
MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1. (26819305)
2016
49
Impaired Japanese encephalitis virus replication in p62/SQSTM1 deficient mouse embryonic fibroblasts. (27624873)
2016
50
CCR5 ameliorates Japanese encephalitis via dictating the equilibrium of regulatory CD4(+)Foxp3(+) T and IL-17(+)CD4(+) Th17 cells. (27439902)
2016

Variations for Japanese Encephalitis

About this section

Expression for genes affiliated with Japanese Encephalitis

About this section
Search GEO for disease gene expression data for Japanese Encephalitis.

Pathways for genes affiliated with Japanese Encephalitis

About this section

Pathways related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 14)
idSuper pathwaysScoreTop Affiliating Genes
19.4IFNB1, TNF
29.1CD209, IFNB1, TNF
3
Show member pathways
9.0CXCL10, IFNB1, TNF
48.9CCL5, CXCL10, TNF
58.9CCL5, CXCL10, TNF
68.9CCL5, IFNB1, TNF
78.8CD209, CLEC4M, IFNB1, TNF
8
Show member pathways
8.5CXCL10, DDX58, IFNB1, TNF
9
Show member pathways
8.3CD209, IFNB1, TLR3, TNF
108.1DDX58, IFNB1, TLR3, TNF
11
Show member pathways
7.7CCL5, CXCL10, DDX58, IFNB1, TLR3
127.6CCL5, CXCL10, DDX58, TLR3, TNF
13
Show member pathways
7.1CCL5, CXCL10, DDX58, IFNB1, TLR3, TNF
14
Show member pathways
6.5CCL5, CD209, CLEC4M, CXCL10, DDX58, IFNB1

GO Terms for genes affiliated with Japanese Encephalitis

About this section

Biological processes related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 38)
idNameGO IDScoreTop Affiliating Genes
1antigen processing and presentationGO:001988210.6CD209, CLEC4M
2cell-cell recognitionGO:000998810.6CD209, CLEC4M
3modulation by virus of host morphology or physiologyGO:001904810.6CD209, CLEC4M
4peptide antigen transportGO:004696810.6CD209, CLEC4M
5positive regulation of monocyte chemotaxisGO:009002610.3CCL5, CXCL10
6positive regulation of T cell migrationGO:200040610.3CCL5, CXCL10
7positive regulation of innate immune responseGO:004508910.2CCL5, IFNB1
8negative regulation of myoblast differentiationGO:004566210.2CXCL10, TNF
9adaptive immune responseGO:000225010.2CD209, CLEC4M, IFNB1
10leukocyte cell-cell adhesionGO:000715910.1CCL5, CD209, CLEC4M
11lipopolysaccharide-mediated signaling pathwayGO:003166310.1CCL5, TNF
12positive regulation of fever generationGO:003162210.1CCL5, TNF
13positive regulation of osteoclast differentiationGO:004567210.0CCL5, TNF
14cellular response to dsRNAGO:007135910.0IFNB1, TLR3
15cellular response to exogenous dsRNAGO:007136010.0IFNB1, TLR3
16cellular response to interferon-betaGO:003545810.0IFNB1, TLR3
17protein kinase B signalingGO:00434919.9CCL5, TNF
18response to salt stressGO:00096519.9CCL5, TNF
19detection of virusGO:00095979.9DDX58, TLR3
20viral genome replicationGO:00190799.9CD209, CLEC4M
21virion attachment to host cellGO:00190629.9CD209, CLEC4M
22positive regulation of interferon-beta productionGO:00327289.9DDX58, TLR3
23viral entry into host cellGO:00467189.8CD209, CLEC4G, CLEC4M
24extrinsic apoptotic signaling pathwayGO:00971919.8TLR3, TNF
25necroptotic signaling pathwayGO:00975279.8TLR3, TNF
26positive regulation of chemokine biosynthetic processGO:00450809.8TLR3, TNF
27positive regulation of chemokine productionGO:00327229.8TLR3, TNF
28positive regulation of NF-kappaB import into nucleusGO:00423469.7TLR3, TNF
29negative regulation of viral genome replicationGO:00450719.6CCL5, IFNB1, TNF
30defense response to virusGO:00516079.5CXCL10, IFNB1, TLR3
31defense response to bacteriumGO:00427429.3IFNB1, TLR3, TNF
32response to exogenous dsRNAGO:00433309.3DDX58, IFNB1, TLR3
33innate immune responseGO:00450879.2CD209, CLEC4M, DDX58, TLR3
34positive regulation of interleukin-6 productionGO:00327559.2DDX58, TLR3, TNF
35positive regulation of interleukin-8 productionGO:00327579.2DDX58, TLR3, TNF
36inflammatory responseGO:00069548.8CCL5, CXCL10, TLR3, TNF
37positive regulation of transcription from RNA polymerase II promoterGO:00459448.3CXCL10, DDX58, IFNB1, TLR3, TNF
38response to virusGO:00096157.6CCL5, CXCL10, DDX58, IFNB1, TLR3, TNF

Molecular functions related to Japanese Encephalitis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mannose bindingGO:000553710.4CD209, CLEC4M
2peptide antigen bindingGO:004260510.4CD209, CLEC4M
3virion bindingGO:004679010.3CD209, CLEC4M
4virus receptor activityGO:00016189.5CD209, CLEC4G, CLEC4M

Sources for Japanese Encephalitis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet